News & Events about Akero Therapeutics Inc.
Globe Newswire
2 months ago
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial...
Globe Newswire
4 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as ...
Globe Newswire
4 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the ...
Globe Newswire
7 months ago
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the...
Ticker Report
7 months ago
Akero Therapeutics, Inc. (NASDAQ:AKRO Get Rating) Director Seth Loring Harrison sold 4,515 shares of the businesss stock in a transaction dated Tuesday, October 25th. The shares were sold at an average price of $44.92, for a total value of $202,813.80. Following the completion of the ...